OncoMatch/Clinical Trials/NCT05211895
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Is NCT05211895 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Durvalumab and Domvanalimab for non-small cell lung cancer.
Treatment: Durvalumab · Domvanalimab — This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) expression ≥ 1% (≥ 1%)
Required: EGFR wild-type
Disease stage
Required: Stage III
Performance status
WHO 0–1
Prior therapy
Must have received: platinum-based chemotherapy — concurrent with radiation therapy
Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy
Must have received: radiation therapy — concurrent with platinum-based chemotherapy
Participants must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy) as part of the chemoradiation therapy
Cannot have received: sequential chemoradiation therapy
Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Chandler, Arizona
- Research Site · Phoenix, Arizona
- Research Site · Fountain Valley, California
- Research Site · Santa Rosa, California
- Research Site · Washington D.C., District of Columbia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05211895 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior sequential chemoradiation therapy disqualifies patients from enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 expression ≥ 1% is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify